tert-butyl 7-(4-(ethoxycarbonyl)-4-methylpiperidin-1-yl)-5-oxa-2,6-diazaspiro[3.4]oct-6-ene-2-carboxylate 、 5-cyclopropyl-2-ethoxybiphenyl-3-carbaldehyde 以the title compound was obtained in the similar manner as in Step G of Example 1的产率得到ethyl 1-(2-((5-cyclopropyl-2-ethoxybiphenyl-3-yl)methyl)-5-oxa-2,6-diazaspiro[3.4]oct-6-en-7-yl)-4-methylpiperidine-4-carboxylate
5-cyclopropyl-2-ethoxy-3-iodobenzaldehyde 、 苯硼酸 以the title compound was obtained in the similar manner as in Step K of Example 88的产率得到5-cyclopropyl-2-ethoxybiphenyl-3-carbaldehyde
[EN] SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS<br/>[FR] DÉRIVÉS DE SPIRO AZÉTIDINE ISOXAZOLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE SSTR5
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2014142363A1
公开(公告)日:2014-09-18
Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS
申请人:Takeda Pharmaceutical Company Limited
公开号:EP2970331A1
公开(公告)日:2016-01-20
US9605000B2
申请人:——
公开号:US9605000B2
公开(公告)日:2017-03-28
HETEROCYCLIC COMPOUND
申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:US20160060273A1
公开(公告)日:2016-03-03
Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.